Wechselwirkungen · Etcamah
Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-153223 · Präparat HOS-100955
P-gp sensitive substrates In vitro data show that camizestrant is an inhibitor of P-glycoprotein (P-gp). Therefore, camizestrant may increase the exposure levels of medicinal products that are substrates of P-gp including but not limited to: edoxaban, digoxin, fexofenadine and dabigatran etexilate. No in vivo clinical data is available. Medicinal products which have a narrow therapeutic index and are sensitive substrates of P- gp should be avoided. Those medicinal products which are sensitive substrates of P-gp are permitted but caution should be exercised and patients monitored closely for possible drug interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fexofenadine (HOS-086255) digoxin (HOS-086172) edoxaban (HOS-086234) camizestrant (HOS-153187) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage 223d6a68f536565da3952db58bfc5f79d9dc3cb9cf1e1f8510b31d05b3986f1d · Zeichen 5152–5777 im Abschnitt